(Q54085337)

24 May 2018

title

Comparative efficacies of levofloxacin and ciprofloxacin against Streptococcus pneumoniae in a mouse model of experimental septicaemia. (English)

1 reference

24 May 2018

main subject

Streptococcus pneumoniae

1 reference

1 reference

Onyeji CO

1

1 reference

24 May 2018

Bui KQ

2

1 reference

24 May 2018

Owens RC Jr

3

1 reference

24 May 2018

Nicolau DP

4

1 reference

24 May 2018

Quintiliani R

5

1 reference

24 May 2018

Nightingale CH

6

1 reference

24 May 2018

publication date

1 July 1999

1 reference

24 May 2018

International Journal of Antimicrobial Agents

published in

1 reference

24 May 2018

volume

12

1 reference

24 May 2018

issue

2

1 reference

24 May 2018

page(s)

107-114

1 reference

24 May 2018

Susceptibilities of bacterial isolates from patients with cancer to levofloxacin and other quinolones

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900087-9

7 January 2021

In vitro antimicrobial activity of CP-99,219, a novel azabicyclo-naphthyridone

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900087-9

7 January 2021

Levofloxacin in vitro activity: results from an international comparative study with ofloxacin and ciprofloxacin

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900087-9

7 January 2021

In-vitro activity of levofloxacin (l-ofloxacin), ofloxacin and ciprofloxacin against clinical isolates of Streptococcus pneumoniae obtained in England and Wales

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900087-9

7 January 2021

Levofloxacin. A review of its antibacterial activity, pharmacokinetics and therapeutic efficacy

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900087-9

7 January 2021

In vitro and in vivo antibacterial activities of levofloxacin (l-ofloxacin), an optically active ofloxacin

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900087-9

7 January 2021

Chemotherapeutic activity of levofloxacin (HR 355, DR-3355) against systemic and localized infections in laboratory animals

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900087-9

7 January 2021

Pharmacokinetic profiles of ciprofloxacin after single intravenous and oral doses

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900087-9

7 January 2021

Streptococcus pneumoniae resistant to penicillin and chloramphenicol

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900087-9

7 January 2021

Emergence of Multiply Resistant Pneumococci

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900087-9

7 January 2021

Activity of CP 99,219 (trovafloxacin) compared with ciprofloxacin, sparfloxacin, clinafloxacin, lomefloxacin and cefuroxime against ten penicillin-susceptible and penicillin-resistant pneumococci by time-kill methodology

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900087-9

7 January 2021

Pneumococcal bacteremia during ciprofloxacin therapy for pneumococcal pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900087-9

7 January 2021

Interspecies scaling, allometry, physiological time, and the ground plan of pharmacokinetics.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900087-9

7 January 2021

Comparison of the bactericidal activities of ofloxacin and ciprofloxacin alone and in combination with ceftazidime and piperacillin against clinical strains of Pseudomonas aeruginosa

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900087-9

7 January 2021

Open-label crossover study to determine pharmacokinetics and penetration of two dose regimens of levofloxacin into inflammatory fluid

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900087-9

7 January 2021

Penetration of fleroxacin and ciprofloxacin into skin blister fluid: a comparative study

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900087-9

7 January 2021

Animal models in the evaluation of antimicrobial agents

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900087-9

7 January 2021

Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900087-9

7 January 2021

Pharmacodynamics of a fluoroquinolone antimicrobial agent in a neutropenic rat model of Pseudomonas sepsis

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900087-9

7 January 2021

Evaluation of the efficacy of ciprofloxacin against Streptococcus pneumoniae by using a mouse protection model

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900087-9

7 January 2021

Pharmacodynamics of amikacin in vitro and in mouse thigh and lung infections

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900087-9

7 January 2021

Cefepime and amikacin synergy against a cefotaxime-susceptible strain of Enterobacter cloacae in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900087-9

7 January 2021

Evaluation of methods for producing renal dysfunction in rats

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900087-9

7 January 2021

Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900087-9

7 January 2021

Bactericidal effect of polymorphonuclear neutrophils on antibiotic-induced filaments of gram-negative bacilli

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900087-9

7 January 2021

Interactions between antibiotics and human neutrophils in the killing of staphylococci.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900087-9

7 January 2021

Quantitative effect of granulocytes on antibiotic treatment of experimental staphylococcal infection

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900087-9

7 January 2021

Postantibiotic leukocyte enhancement: increased susceptibility of bacteria pretreated with antibiotics to activity of leukocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900087-9

7 January 2021

10.1016/S0924-8579(98)00087-9

Identifiers

DOI

1 reference

24 May 2018

1 reference

24 May 2018